Results showed that the average CEACAM5 promoter methylation percentage in the tumor part was 17% ± 6%, whereas that of a matched adjacent normal part was 20% ± 3% (p < 0.001; Figure 4C). The gene discussed is CEACAM5; the disease is neoplasm.